TURKU, FINLAND – March 23, 2026 – DelSiTech Ltd, a leader in biodegradable silica-based drug delivery technologies, today announced the appointment of Laura Chirica as Chief Executive Officer. She will assume her role in April 2026.
Örjan Andersson, Chairman of the Board, commented: “We are delighted to welcome Laura Chirica, Ph.D., as DelSiTech’s new CEO. Laura has more than 25 years of experience in commercial and leadership roles across the biotech, medtech, and biopharmaceutical industries. She is exceptionally well positioned to lead DelSiTech through its next phase of growth and to deliver on our strategic ambitions.”
Laura Chirica added: “I am thrilled to join DelSiTech at such an exciting and transformational time. I look forward to leveraging my experience in building and scaling commercial operations and strategic partnerships to create value for patients, partners, and shareholders.”
Prior to joining DelSiTech, Laura served as CEO of Cellevate AB, a Swedish biotech company focused on proprietary nanofiber technology for next-generation cell culture systems in biomanufacturing. During her tenure, the company gained a top position as an innovative supplier and emerging force in industrial bioprocessing for advanced biotherapies, secured key intellectual property, completed successful financing rounds, and established strategic global partnerships.
Earlier in her career, Laura held senior commercial roles in sales and marketing at Immunovia, Svar Life Science, Sartorius Stedim Biotech, Agilent Technologies, and Cytiva.
Laura holds a BSc in Biotechnology, an MSc in Food Biotechnology, and a PhD in Medical Biochemistry from Umeå University.
The Board also extends its sincere thanks to Martti Hedman for his leadership as Interim CEO over the past five months, during which he ensured continuity in the execution of the company’s strategy.